Page 1 of 3

	محمد فحد مرسوس عربي		Page 1 0		·		
1	Form PTO-1449	Atty. Docket: 452005-150			Serial No.: Unassigned		
INFORMAT	TION DISCLOSURES	STATEMENT			1		
			Applicant: Bulwani e	et al.			
			Filing Date: September 17, 2003 Group: Unassigned			nassigned	
		U.S. PA	TENT DOCUMENTS				
Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date	
/KC/	6,462,094	10/8/02	Dang et al.	514	849	8/22/01	
/KC/	6,417,206 B1	7/9/02	Leflein et al.	514	352	1/26/01	
/KC/	6,306,904 B1	10/23/01	Gordziel	514	530	7/25/00	
/KC/	6,287,597 B1	9/11/01	Gordziel	424	464	3/12/99	
/KC/	6,037,358	3/14/00	Gordziel	514	357	3/24/99	
/KC/	5,807,579	9/15/98	Vilkov et al.	424	469	11/14/96	
/KC/	5,663,415	9/2/97	Chopdekar et al.	560	68	6/28/96	
/KC/	5,599,846	2/4/97	Chopdekar et al.	514	653	6/28/96	
/KC/	5,164,398	11/17/92	Sims et al.	514	282	4/1/91	
/KC/	4,601,714	7/22/86	Burnhill	604	286	3/7/84	
		FOREIGN	PATENT DOCUMENT	s			
Examiner Initial	Document Number	Date	Country	Class	Sub- Class	Translation	
/KC/	64,007,786 (abstract)	8-31-93	JP				
/KC/	06287144	01-02-95	JP				
/KC/	39007786	05-18-64	JP			YES	
	OTI	IER (Including Auth	nor, Title, Date, Pertine	ent Pages, etc.)	_ 		
/KC/	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Weiler et al., "Randomized, double blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinits using an acute model," Annals of Allergy, vol. 64(1): 63-67						
/KC/		Goldberg et al., "Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders," Clinical Medicine, vol. 72(9): 1475-1479.					
/KC/	TRIPLE TANNA	TRIPLE TANNATE, Drug Launches (doc. #: 0182701) 5/99					
/KC/	TUSSI-12, Drug	TUSSI-12, Drug Launches (doc. #: 0179128) 3/99					
/KC/	TUSSI-12, Drug	TUSSI-12, Drug Launches (doc. #: 0176901) 12/98					
Examiner:	/Kendra	/Kendra Carter/ Date Considered: 01/25/2008					
XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

Page 2 of 3

			Atty. Docket:		Serial No).:	
Form PTO-1449			452005-150	1 • • • • • • • • • • • • • • • • • • •		Unassigned	
INFORMATION DISCLOSURE STATEMENT							
			Applicant: Bulwani	et al.			
			Filing Date: Septem	Filing Date: September 17, 2003 Group: Unassigned			
		U.S. 1	PATENT DOCUMENTS				
Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date	
/KC/	B1 4552,899	10/20/92	Sunshine et al.	514	568	4/9/84	
/KC/	4,552,899	11/12/85	Sunshine et al.	514	568	4/9/84	
/KC/	3,061,517	10/30/62	Walter	167	65	2/16/62	
/KC/	3,018,221	1/23/62	Millar et al.	167	65	3/28/58	
/KC/	2,798,024	7/2/57	Zappas et al.	167	82	6/2/54	
/KC/	2,757,124	7/31/56	Wolff	167	82	3/8/52	
/KC/	20010011104	8/2/01	Gordziel	514	653	12/11/98	
	ОТІ	IER (Including Au	uthor, Title, Date, Pertin	ent Pages, etc.)		
/KC/	R-TANNATE, Drug Launches (doc. #: 0172212) 8/98						
/KC/	TRIPLE TANNATE, Drug Launches (doc. #: 0163340). 1/98						
/KC/	ATROHIST, Drug Launches (doc. #: 0154800). 5/97						
/KC/	GELHIST, Drug Launches (doc. #: 015445). 5/97						
/KC/	PHENATAN, Dr	PHENATAN, Drug Launches (doc. #: 0149758) 1/97					
/KC/	TRIOTANN, Drug Launches (doc. #: 0136052) 12/95						
/KC/	TRI-TANNATE, Drug Launches (doc. #: 0129566) 6/95						
/KC/	RICOBIN-D, Drug Launches (doc. #: 0129564) 6/95						
/KC/	RICOBID, Drug Launches (doc. #: 0129563) 6/95						
/KC/	QUAD-TUSS TA	QUAD-TUSS TANNATE, Drug Launches (doc. #: 0127440) 4/95					
/KC/	TRI-TANNATE, Drug Launches (doc. #: 0179121) 3/99						
/KC/	TRITAN, Drug Launches (doc. #: 0144945) 9/96						
/KC/	TRI-NATAN, Dr.	TRI-NATAN, Drug Launches (doc. #: 0110372) 11/93					
/KC/	R-TANNATE, DI	R-TANNATE, Drug Launches (doc. #: 0110158) 11/93					
/KC/	TRIN TUSS, Drug Launches (doc. #: 0049139) 3/93						
Examiner:	/Kendra	Carter/		Date Cons	sidered:	01/25/2008	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

Page 3 of 3

		Atty. Docket:	Serial	! No.:				
Form PTO-1449		452005-150	Unas	signed				
INFORMATION DISCLOSURE STATEMENT								
			Applicant: Bulwani et al.					
			Filing Date: September 17, 2	2003 Group	p: Unassigned			
		OTHER (Including Autho	or, Title, Date, Pertinent Page	es, etc.)				
/KC/		TANORAL , Drug Launches (doc. #: 00	044406) 4/92					
/KC/		HISTATUSS, Drug Launches (doc. #: 0041022) 7/91						
/KC/		TRI-TANNATE, Drug Launches (doc. #: 0020282) 9/87						
/KC/		TRI-TANNATE, Drug Launches (doc#: 1002267) 9/97						
/KC/		TANORAL, Drug Launches (doc#: 1025217) 4/92						
/KC/		"Robitussin et seq." Physician's Desk Reference, 33rd Ed., 1979, pages 1424-1425						
/KC/		Wilson and Grisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, Ninth Ed. 1991, pages 423 & 425.						
		,						
Examiner:		/Kendra Carter/	Date	e Considered:	01/25/2008			
EXAMINER:		Initial if reference considered, wheth citation if not in conformance and no Applicant.						